Sources of Adult Mesenchymal Stem Cells Applicable for Musculoskeletal Applications - A Systematic Review of the Literature by Mafi, R et al.
242 The  Open  Orthopaedics  Journal, 2011, 5, (Suppl 2-M2) 242-248   
 
  1874-3250/11  2011 Bentham Open 
Open Access 
Sources of Adult Mesenchymal Stem Cells Applicable for Musculoskeletal 
Applications - A Systematic Review of the Literature 
R. Mafi
1, S. Hindocha
*,2,3, P. Mafi
1, M. Griffin
2 and W.S. Khan
4 
1The Hull York Medical School, Hertford Building, Hull, HU6 7RX, UK 
2Manchester Interdisciplinary Biocentre, University of Manchester, 131 Princess Street, M17DN, UK 
3Department of Plastic Surgery, Whiston General Hospital, Liverpool, L355DR, UK 
4University College London Institute of Orthopaedics and Musculoskeletal Sciences, Royal National Orthopaedic 
Hospital, Stanmore, Middlesex, HA7 4LP, UK 
Abstract: Mesenchymal stem cells (MSCs) were first discovered by Friedenstein and his colleagues in 1976 from bone 
marrow. The unique property of these cells was their potential to develop into fibroblastic colony forming cells. Since 
Friedenstein’s discovery of these cells the interest in adult MSCs has been progressively growing. Nowadays MSCs are 
defined as undeveloped biological cells capable of proliferation, self renewal and regenerating tissues. All these properties 
of MSCs have been discovered in the past 35 years. MSCs can play a crucial role in tissue engineering, organogenesis, 
gene therapy, transplants as well as tissue injuries. These cells were mainly extracted from bone marrow but there have 
been additional sources for MSCs discovered in the laboratories including: muscle, dermis, trabecular bone, adipose 
tissue, periosteum, pericyte, blood, synovial membrane and so forth. The discovery of the alternative sources of MSCs 
helps widen the application of these cells in different areas of medicine. By way of illustration, they can be used in various 
therapeutic purposes such as tissue regeneration and repair in musculoskeletal diseases including osteonecrosis of femoral 
head, stimulating growth in children with osteogenesis imperfecta, disc regeneration, osteoarthritis and duchenne 
muscular dystrophy. In order to fully comprehend the characteristics and potential of MSCs future studies in this field are 
essential. 
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  Thirty five years ago Friedenstein et al. discovered 
mesenchymal stem cells (MSCs) in the bone marrow where 
he observed a certain population of cells that developed into 
fibroblastic colony forming cells (CFU-F) [1]. MSCs 
account for a very small ratio of the bone marrow and it has 
been estimated that 1/10000 to 1/100000 of the bone marrow 
nuclear cells are MSCs [2, 3]. Since the ground breaking 
discovery of these cells, the interest in adult MSCs has been 
growing and other sources of the adult MSCs have been 
identified by scientists. The new sources of adult MSC can 
be used for various therapeutic purposes such as tissue 
regeneration and repair in musculoskeletal diseases [4]. 
Despite their therapeutic and clinical significance, there are 
no articles bringing together and comparing the sources of 
MSCs and their various applications in musculoskeletal 
conditions. In this systematic review, studies have been 
searched for different sources of adult MSCs as well as the 
recent musculoskeletal applications using adult MSCs. These 
studies were predominantly searched using AMED, 
CINAHL, EMBASE, Medline, PubMed and ZETOC. The 
aim of this study is to summarize all the available literature 
relating to sources of adult MSCs and their application in 
musculoskeletal diseases. 
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  Stem cells are defined as undeveloped biological cells 
capable of proliferation, self renewal, conversion to 
differentiated cells, and regenerating tissues. There are two 
main types of stem cells in mammals [5]; embryonic stem 
cells (ESC) are pluripotent cells derived from the inner cell 
mass of blastocyts which are formed several days after an 
egg is fertilised, and nonembrionic stem cells (non-ESC) 
also known as adult stem cells as they are usually attained 
from the bone marrow of adults. There are two types of stem 
cells from this source: Haemopoietic, that differentiate into 
blood cells, and MSCs. Less mature tissue sources including 
umbilical cord blood, placenta and fetal somatic tissues are 
ranked among the non-ESCs. Furthermore, the fetal stem 
cells (FSCs) are regarded as an intermediate cell type 
between ESCs and adult stem cells. FSCs are obtained from 
the gonads in the first trimester of development [5, 6]. 
  It has been more than 130 years that the existence of non-
hematopoietic stem cells was proposed by the German 
pathologist Cohneim. He suggested that bone marrow can 
aid the wound healing process in various peripheral tissues 
[7, 8]. This theory was confirmed by Friedenstein in the 
1970’s. He discovered that the bone marrow consisted of 
fibroblastoid cells with clonogenic potential in vitro which 
are capable of forming colonies (CFU-F). Furthermore, 
Friedenstein proved that it was achievable to regenerate 
heterotopic bone tissue in different transplants. This way he 
provided evidence in support of the self renewal potential of 
these cells [1]. Ever since, numerous scientists have Sources of Stem Cells  The Open Orthopaedics Journal, 2011, Volume 5    243 
confirmed those findings and have expanded on them by 
showing that the cells isolated by Friedenstein were also 
present in human bone marrow. Moreover, they 
demonstrated that these cells could be differentiated in vitro 
into cells with mesenchymal lineages such as adiopocytes, 
chondrocytes, myoblasts and osteoblasts [9]. Therefore, cells 
isolated by Friedenstein were named MSCs by Caplan and 
colleagues [10]. 
  After the discovery of the MSCs, it has progressively 
become clear that these cells could be the basis for a natural 
system of tissue repair [11]. In various studies MSCs have 
proven to be an effective therapeutic agent in experimental 
models of tissue injuries [12-14]. According to Prockop et 
al. in the majority of these studies there was little correlation 
between therapeutic efficacy and engraftment efficiency. 
Consequently, the ability to repair is secondary to the 
secretion of soluble factors by MSCs which alter the tissue 
microenvironment [7]. In other words, according to Caplan 
and colleagues MSCs may provide the so called ‘trophic 
activity’ [10]. It has been demonstrated that MSCs in vitro 
produce a variety of factors that are capable of manipulating 
a broad range of biological functions. Among the most 
important are angiogenesis, secretion of neuroregulatory 
peptides and cytokines that have crucial role in inflammation 
and repair [10]. 
  Further investigations in the biology of MSCs in the in 
vivo setting will provide an important insight into cellular 
mechanisms of angiogenesis, bone development, 
hematopoiesis and vasculogenesis. Despite numerous studies 
which correlate CFU-Fs to bone mass there is still no robust 
evidence indicating that MSCs are the skeletal stem cells 
[15, 16]. Significant information is gathered concerning the 
use of MSCs for tissue engineering purposes. Scientists 
identified various modalities of expanding bone marrow as 
well as adipose tissue MSCs while retaining their 
multipotency [7, 10]. These cells have only been 
experimented on animal models to form tissues such as bone 
and cartilage at specific sites thus, there is no MSC 
technology for humans available [7]. 
 According  to  Phinney  et al., if the MSCs develop into a 
natural system of tissue repair then it is essential to know 
how these cells are able to reach the site of injury. 
Chamberlian et al. point out the chemokines including SDF1 
and its cognate receptor CXCR4 to have a significant role in 
guiding MSCs to sites of injury [17]. A more recent study by 
Belema-Bedada  et al. suggests that the cytokine receptor 
CCR2 and the intercellular adaptor molecule FROUNT serve 
in a similar way to SDF1 for taking the bone marrow derived 
MSCs to various sites for repair [18]. Despite these studies, 
there is not sufficient information regarding the mobilization 
of the MSCs from the bone marrow. Rochefort et al. claim 
that MSCs can be perceived in circulating blood and the 
circulating pool can increase by exposure to chronic hypoxia 
[19]. However, the precise mechanism of this phenomenon 
remains an enigma. 
  MSCs can be distinguished from the hematopoietic stem 
cells (HSCs) by their cell surface antigens which create a 
phenotypic separation from HSCs. Therefore identification 
of cell-specific cell surface markers on MSCs is of great 
importance. Numerous cell-surface antigens expressed by the 
MSCs have been identified but only very few scientists 
managed to establish a phenotypic characterization of MSCs 
in vivo [20]. 
  In 1980’s, Simmons et al. managed to isolate an antibody 
called STRO1 that could recognize the cell surface antigen in 
human MSCs. The cell population identified by this antibody 
were referred to as STRO-1 positive cells and were able to 
generate CFU-Fs and differentiate into multiple 
mesenchymal lineages in vitro [21].  More recently it was 
reported that by positive selection for VCAM/CD106 the 
degree of homogeneity of the STRO-1 positive cells could 
be more enhanced [22]. In addition to that, MCAM/CD146 
positive cells isolated from BM-MSCs hold on plastic in 
vitro and are clonogenic. Other properties of these cells 
include self-renewal in vitro, generating bone and a 
hematopoietic supportive microenvironment in transplants 
done in mice [23]. The relationship between the 
MCAM/CD146 positive cells and the ones reported by 
Simmons et al. needs to be elucidated. 
  Simmons and colleagues have also identified a bone 
marrow pool of CD45 (-) CD31 (-) cells which appear to 
consist of MSCs [24, 25]. CD45 and CD31 are pan-
hematopoietic and endothelial cell markers respectively and 
were broadly used in this study to negatively select for 
hematopoietic as well as endothelial cells. Interestingly, a 
study led by Rogers et al. has also shown that a subset of 
CD45 (+) Lin (-) bone marrow cells could differentiate in 
vivo into different cells including endothelial cells, 
osteoblasts, muscle cells and natural cells. This finding 
contradicts the nature of CD45 as a marker of hematopoietic 
cells and can be used to redefine the boundary between 
HSCs and MSCs. 
  In the previous decade, MSCs have been used by 
scientists for gene therapy in experimental models and to 
treat certain conditions including osteogenesis imperfecta in 
humans. In order to use MSCs as permanent therapeutic 
agents in the future, more research is required [26, 27]. 
  One of the most significant features of MSCs that is 
worth considering is their extraordinary and unexplained 
immunomodulartory properties. It has been reported that the 
adult MSCs express intermediate levels of class I major 
histocompatibility complex (MHC) proteins but no class II 
MHC proteins. Therefore, this phenotype is classified as 
non-immunogenic, which indicates that no 
immunosuppression is required in a transplant into an 
allogenic host [28]. Further studies have shown that MSCs 
have immunosuppressive properties by modulating specific 
T-cell functions in vitro and can be translated into in vivo 
setting in experimental models [29, 30]. 
MATERIALS AND METHODS 
  The relevant articles for this review were searched 
primarily from the electronic data bases AMED, ASSIA 
(CSA Illumina), CINAHL (EBSCO), Conference 
Proceedings Citation Index: Science (ISI) on Web of 
Knowledge, EMBASE, Medline, PREMEDLINE In-Process 
& Non-Indexed Citations (OvidSP), PsycINFO (OvidSP), 
PubMed, Science Citation Index (ISI) on Web of 
Knowledge, Social Sciences Citation Index (ISI) on Web of 
Knowledge and Cochrane Library (Wiley) and ZETOC. The 
following key words were used for citing the appropriate 
articles: mesenchymal stem cells, stem cells, MSC 244    The Open Orthopaedics Journal, 2011, Volume 5  Mafi et al. 
applications, musculoskeletal applications, tissue 
engineering and muscular dystrophy. 
  The following inclusion criteria were used to select 
relevant studies: A) Identified sources of MSCs in adult 
humans, B) Contained information about the applicability of 
MSCs in musculoskeletal conditions. C) Articles using 
animal MSCs for human applications. Articles which were 
excluded: A) did not include MSCs B) Involved stem cells 
not found in adults, e.g. embryonic stem cells, C) Failed to 
refer to potential uses of MSCs in musculoskeletal diseases. 
Out of 151 articles and studies that were viewed 78 were 
found relevant and suited the inclusion criteria. 
RESULTS 
  The relevant information from the included articles is 
summarized in Tables 1 and 2. 
  As presented in Table 1, new sources for adult MSCs 
have been found since 1976. Adult stem cells have the 
ability to differentiate into more than one cell type, but 
unlike the embryonic stem cells they are often restricted to 
certain types or ‘lineages’ [51, 52]. MSCs have the potential 
to differentiate into chondrocytes, osteoblasts, adipocytes, 
fibroblasts, marrow stroma, and other tissues of 
mesenchymal origin [4]. According to the studies 
summarized in Table 1, the MSCs derived from the bone 
marrow have a higher transdifferentiation ability than 
Mesenchymal cells of different origin which can 
differentiate into 11 types of cells. The bone marrow aspirate 
is currently considered the most enriched and accessible 
source of MSCs but according to Tuan et al. [4]. An 
alternative source such as trabecular bone could take its 
place, in view of recent efficient isolation of multipotential 
cells from this tissue [4]. A recent study by Sart et al. [53] 
argues that ear MSCs bear the characteristics of progenitor 
cells because of their ability to be differentiated into the 
three lineages of osteocytes, adipocytes and chondrocytes. 
Furthermore, it was found that Ear-MSCs had a threefold 
higher cell growth rate compared to bone marrow derived 
MSCs. According to Shi et al. [54] there are also other 
sources for MSCs that have been discovered such as 
umbilical cord blood, amniotic fluid, placenta, dental pulp, 
tendons, though the complete equivalency of such 
populations has not been formally demonstrated and it is not 
for certain what lineages they can differentiate into. 
DISCUSSION 
  In this systematic review we managed to look at various 
studies that discussed the nature and source of the MSCs and 
reviewed the application of these cells for organogenesis and 
tissue engineering for numerous diseases. Apart from 
summarizing various sources of the adult MSCs their lineage 
differentiation potentials have been pointed out as well. With 
regards to studies in Table 1, MSCs derived from the bone 
marrow have the most differentiation potential among the 
rest, now the question rises whether one should only rely on 
bone marrow derived MSCs for therapeutic applications? 
  According to the literature reviewed, it can be deduced 
that there is great discrepancy whether bone marrow derived 
Table 1.  The Various Sources of Adult MSCS as well as their Multilineage Differentiation 
 
Adult MSCs Sources  Multilineage Differentiation Potential  Authors 
Bone marrow  Adipocyte 
Astrocyte 
Cardiocyocyte 
Chondrocyte 
Hepatocyte 
Mesangial cell 
Muscle 
Neuron 
Osteoblast 
Stromal cell 
Embryonic tissue 
Pittenger et al. [31] 
Kopen et al. [32] 
Fukuda et al. [33] 
Johnstone et al. [34] 
Petersen et al. [35] 
Ito et al. [32] 
Ferrari et al. [36] 
Azizi et al. [37] 
Pittenger et al. [31] 
Majumdar et al. [38] 
Jiang et al. [39] 
Muscle Adipocyte,  Myotubes 
Endothelial Cell, neuron 
Chondrocyte 
Osteocyte 
Wada et al. [40] 
Qu-Petersen et al. [35] 
Adachi et al. [41] 
Bosch et al. [42] 
Dermis  Adipocyte, chondrocyte, osteoblast  Young et al. [43] 
Trabecular bone  Adipocyte, chondrocyte, muscle, osteoblast  Noth et al. [44] 
Adipose tissue  Chondrocyte, muscle 
Osteoblast, Stromal cell 
Zuk et al. [45] 
Gronthos et al. [46] 
Periosteum Chondrocyte,  osteoblast  Nakahara  et al. [47] 
Pericyte Chondrocyte  Diefenderfer  et al. [48] 
Blood  Adipocyte, fibroblast, osteoblast, osteoclast  Zvaifler et al. [49] 
Synovial membrane  Adipocyte, chondrocyte, muscle, osteoblast  De Bari et al. [50] Sources of Stem Cells  The Open Orthopaedics Journal, 2011, Volume 5    245 
MSCs is the best available source to be used or other sources 
of adult MSCs are as good or even better. By taking the 
information of Table 2 into consideration it can be deduced 
that mainly muscle derived MSC‘s are used for muscle 
related applications and bone marrow derived MSC are the 
preferred choice for degenerative bone diseases. 
  When comparing different sources of MSCs, each source 
has its advantages and draw backs. By the way of 
illustration, bone marrow derived stem cells have high 
multilineage differentiation but do not have the greatest cell 
growth rate as Sart et al. [53] in his recent study shows that 
ear derived MSCs have a threefold higher cell growth rate 
compared to bone marrow derived MSCs. MSCs from 
umbilical cord blood have fewest colonies after they have 
been isolated, but they showed a much higher proliferation 
capacity compared to bone marrow derived MSCs. In 
addition to that, adipose tissue derived MSCs showed to 
have greater number of colonies to bone marrow derived 
MSC [58]. Even though bone marrow is easily accessible for 
musculoskeletal applications some studies used other sources 
of adult MSCs. For instance Qu et al. demonstrated that 
MSCs extracted from human umbilical cord healed non-
union significantly quicker than auto-iliac bone 
transplantation [59]. In addition to that Funk et al. states that 
periosteum derived stem cells can aid to heal non-union of 
the distal femur using a 3D matrix. Despite being the first 
MSCs discovered, bone marrow derived MSCs might not be 
the most suitable sources of MSCs for musculoskeletal 
applications. Furthermore, It is interesting to note that in 
Tuan  et al. review [4] and shi et al. [54] they did not 
consider umbilical cord blood, amniotic fluid, placenta, 
dental pulp and tendons as sources of adult MSCs even 
though MSCs can be extracted from them, due to the lack of 
robust scientific evidence [4]. 
  Numerous studies over the years have shown that MSCs 
could potentially become the basis for a powerful ‘natural 
system of tissue repair’ [68]. MSCs have demonstrated their 
ability to serve as effective therapeutic agents in variety of 
experimental models of different tissue injuries [13]. 
Horwitz et al. [26], Gangji et al. [66] and Quarto et al. [65] 
managed to use bone marrow derived MSCs for aiding 
osteonecrosis of femoral head and stimulating growth in 
children with osteogenesis imperfecta. Other studies [60, 62] 
suggest that BM-MSCs as well as muscle derived MSCs can 
be used to regenerate bone and muscle in Duchenne 
muscular dystrophy. One should not overlook the fact that 
these studies have been successful on animals such as rats 
and dogs but no trials on humans have been done. A further 
study combines sand rat AD-MSCs with human annulus 
cells as possible option for cell-based autologous disc 
regeneration [63]. 
  For future advances in MSCs in the field of regeneration 
and tissue engineering it is important to know the exact 
nature of these cells. Therefore, focusing on the cellular and 
genetic signature of MSCs is required. One way to achieve 
this is by investigating other populations of stem cells and 
techniques such as flow cytometry to analyze specific cell-
Table 2.  The Use of Different Sources of MSCs in Musculoskeletal Applications 
 
Author  Source of MSC  Musculoskeletal Application 
Cenni et al. [55]  BM (bone marrow)  Treatment of orthopaedic conditions characterized by large bone defects 
Getgood et al. [56]  Joint/synovium  Simultaneous use of material scaffolds, cells and signalling molecules to attempt to  
modulate the regenerative tissue 
Tuan et al. [4]  Synovium  Adult MSCs as cell source for articular cartilage tissue engineering 
Mitchell et al. [57]  Muscle  PW1+/Pax7 interstitial cells efficiently contribute to skeletal muscle regeneration 
 in vivo as well as generating satellite cells and PICs 
Deans et al. [58]  BM, adipose tissue, umbilical cord  
blood, and amniotic fluid 
Enhancing stem cell differentiation for improving tissue regeneration  
in musculoskeletal diseases such as osteoarthritis 
Qu et al. [59]  Umbilical cord  Healing of non-unions significantly quicker than auto-iliac bone transplantation 
Lee et al. [60]  Muscle  mc13 is capable of differentiating into both myogenic and osteogenic  
lineage in vitro and in vivo thus capable of improving muscle and bone 
 regeneration. Theoretic option for duchenne muscular dystrophy treatment 
Scotti et al. [61]  BM  MSCs developed in vitro hypertrophic tissue structures resulted in accelerated  
formation of larger bony tissues 
Dezawa et al. [62]  BM and muscle  Pax7-positive cells are more ready supply of myogenic cells than the rare  
myogenic stem cells normally found in muscle and bone marrow.  
Theoretic option for Duchenne muscular dystrophy treatment 
Tapp et al. [63]  Adipose tissue  AD-MSC have potential in cell-based therapy for disc degeneration 
Nöth et al. [64]  BM  Osteoarthritis, Rheumatoid arthritis, articular cartilage  
repair and meniscus repair 
Quarto et al. [65]  BM  Could treat ulna, humerus and tibia non-unions 
Gangji et al. [66]  BM  Osteonecrosis of femoral head 
Horwitz et al. [26]  BM  Stimulate growth in children with osteogenesis imperfecta 
Funk et al. [67]  Periosteum  Healing non-union of the distal femur using a 3D matrix 246    The Open Orthopaedics Journal, 2011, Volume 5  Mafi et al. 
surface markers [4]. Furthermore, more specific information 
is required concerning the endogenous function in the adult 
MSCs’ tissues to give a better understanding of their true 
potential for clinical uses. Learning about the role of these 
cells in organogenesis is required in order to adjust in vivo 
repair and regeneration processes without the necessity for in 
vitro expansion. 
  Developing a model that tests for the ability of MSCs to 
self-renew, proliferate and differentiate in vivo could aid to 
investigate more in characterization of the MSCs. By way of 
illustration, a test that is becoming more popular is the 
murine intratibial injection of MSCs and characterization of 
their role in bone homeostasis and fracture repair [69]. 
  An additional achievement in this field would be to 
identify certain pharmacological tools in order to expand in 
vivo and in vitro the mesenchymal stem cell pool. There have 
been investigations in this field and tools such as proteosome 
inhibitor Velcade have been reported to expand the MSC 
pool in a murine model in vivo [70, 71]. 
  In order to identify the appropriate pharmacological tools 
detailed analysis of the complex network of signalling 
pathways and regulatory cells that control the ability of 
MDCs for self-renewal, proliferation and predominantly 
differentiation is required. The identification of this network 
should not be underestimated as it will reveal the rules that 
govern the size of the MSC pool in vivo. This will eventually 
allow appropriate pharmacological interventions which 
would assist in the different applications of the MSCs in 
various diseases. To gain insight into the molecular 
mechanisms of the MSCs a global gene expression profiling 
approach could prove of great assistance [72-77]. 
  Eventually, it is not for certain how valuable the in vivo 
analysis of genetically modified experimental models could 
be for humans. According Riminucci et al. human diseases 
such as fibrous dysplasia can broaden our understanding of 
MSCs, for instance analysis of Gs[alpha] signalling pathway 
in this disease, which involves early cells of osteoblast lineage 
in mosaic individuals, can be a model worth considering [78]. 
CONCLUSION 
  Adult MSCs have various sources and present an exciting 
progenitor cell source for applications of tissue engineering and 
regenerative medicine. Bone marrow was the first source of 
adult MSC but in recent years other sources have been 
identified. Among the most significant are muscle, skin, adipose 
tissue, synovial membrane, dermis, trabecular bone, periosteum, 
pericyte and blood. There is also potential evidence that MSCs 
derived from adult tissues can aid certain musculoskeletal 
diseases such as osteonecrosis of femoral head, stimulating 
growth in children with osteogenesis imperfecta, disc regenerat-
ion, osteoarthritis and duchenne muscular dystrophy. In order to 
fully understand the potential of these cells future studies should 
be directed to ascertain their cellular characteristics and the 
endogenous function of MSCs in normal and abnormal tissues. 
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